Stock Analysis, Dividends, Split History

GHDX / Genomic Health, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,251.71
Enterprise Value ($M)2,197.86
Book Value ($M)225.20
Book Value / Share6.28
Price / Book10.00
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 35,049,436
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 35,324,394
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.02
Return on Assets (ROA)-0.02
Return on Equity (ROE)-0.02
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio5.39
Income Statement (mra) ($M)
Contracts Revenue299,000.00
Sales Revenue Goods Net340,451,000.00
Operating Income-6.45
Net Income-3.86
Earnings Per Share Diluted-0.11
Earnings Per Share Basic And Diluted-0.11
Earnings Per Share Basic-0.11
Cash Flow Statement (mra) ($M)
Cash From Operations30.59
Cash from Investing-42.56
Cash from Financing-42.56
Identifiers and Descriptors
Central Index Key (CIK)1131324
Related CUSIPS
37244C951 37244C901

Split History

Stock splits are used by Genomic Health, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus

2018-10-11 zacks
Myriad Genetics recently signed a commercialization plan with Pfizer Inc. (PFE - Free Report) for FDA approval to use its BRACAnalysis CDx as a companion diagnostic with the latter’s talazoparib. Meanwhile, Thermo Fisher Scientific Inc. (TMO - Free Report) announced the sixth licensing agreement for its B·R·A·H·M·S PCT (procalcitonin) biomarker. In fact, there are many similar developments that clearly point toward the rapid emergence of molecular diagnostics in the MedTech space. (4-0)

Here's Why You Should Invest in Genomic Health (GHDX) Now

2018-10-09 zacks
Genomic Health, Inc. (GHDX - Free Report) has been gaining investor confidence on stellar results over an extended period. Over the past year, the company’s share price has outperformed its industry. The stock has gained 103.2% against the industry’s 18.6% fall. Also, the company has fared better than the S&P 500’s 13.9% rise. (1-0)

Genomic Health's New Data on Oncotype DX GPS to Boost Uptake

2018-10-04 zacks
Genomic Health, Inc. (GHDX - Free Report) recently announced the publication of real-world clinical data supporting the use of the Oncotype DX Genomic Prostate Score (GPS) test, which has resulted in substantially greater use of active surveillance compared to no testing. Results of this new study were published in Reviews in Urology. (3-1)

Quest Diagnostics Buys PhenoPath, Grows in Anatomic Pathology

2018-10-02 zacks
Quest Diagnostics Incorporated (DGX - Free Report) has purchased PhenoPath, a national provider of specialized anatomic pathology (AP) and related services. The acquisition is expected to accelerate the company’s growth strategy for advanced diagnostics. However, financial terms of the deal have been kept under wraps.

Women Health a Prime Concern Worldwide: 3 Stocks in Focus

2018-09-28 zacks
Over the last few years, the ongoing debate about the effect of women’s health improvements on economic development is finally being taken as a matter of utmost relevance. However, the gap between words and action is still obvious as apparent from women of emerging countries whose limited or almost no access to education and employment make them extremely susceptible to life-threatening ailments. (15-0)

CUSIP: 37244C101